Application

DL-Homocysteine has been used to induce hyperhomocysteinemia in Sprague–Dawley rats. It has also been used to study the effects of hyperhomocysteinemia on atherosclerosis in apolipoprotein E-deficient mice.

Biochem/physiol Actions

Increased plasma homocysteine is a risk factor for coronary heart disease and carcinogenesis; may be a marker for tumor cell growth.

Homocysteine is a sulfhydryl-containing amino acid, synthesized from methionine. It is a non-essential, non-proteinogenic amino acid. It is an important determinant of the methylation cycle and is present in the plasma in four forms. An abnormally high level of homocysteine leads to hyperhomocysteinemia and also promotes atherosclerosis.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. H4628.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Packaging

10 mg in autosample vial

1, 5, 25 g in poly bottle